We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Supreme Court decided this week not to hear a case that would have decided the legality of reverse-payment agreements, which an FTC legal expert recently called the single greatest threat to generic drug competition.